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KAJIAN BIOPEROLEHAN ANDROGRAPHOLIDE DALAM TIKUS 
ABSTRAK 
Satu kaedah analisis kromatografi cecair prestasi tinggi yang mudah, sensitif and 
khusus telah dibangunkan dan disahkan untuk pengesanan dan kuantifikasi 
andrographolide di dalam plasma. Kaedah ini adalah linear dari 31.3ng/mL hingga 
2000ng/mL. Nilai koefisi variasi untuk dalam hari dengan antara hari pengesahan adalah 
kurang daripada 12%. Nilai kejituan untuk dalam hari dengan masing-masing antara hari 
adalah di antara 90.3% - 103.3% dan 93.5% - 103.9%. Pemulihan mutlak untuk 
andrographolide adalah lebih daripada 67%. Andrographolide stabil dalam larutan 
sehingga 6 bulan. Walau bagaimanapun, ia hanya stabil dalam plasma sehingga 2 jam, 
mungkin kerana terikat kepada protein. Andrographolide tulen adalah kurang larut 
dalam air. Apabila dicampur dengan polimer polyvinylpyrrolidone (PVP) K25, 
kelarutan andrographolide dalam air meningkat. Penyelidikan in vitro menunjukkan 
bahawa kebolehlarutan andrographolide meningkat apabila jumlah PVP K25 ditambah. 
Kompleks andrographolide-PVP K25 adalah stabil pada pH1.2, 4.5 dan 7.0 sehingga 8 
jam, dengan lebih daripada 90% kekal dalam larutan. Penyelidikan in vivo dalam tikus 
menunjukkan bahawa andrographolide tulen tidak dapat dikesan dalam plasma 
walaupun diberi dos setinggi 50mg/kg. Walau bagaimanapun, dengan 
mencampurkannya dengan PVP K25, sejenis polimer yang larut dalam air, bioperolehan 
oral andrographolide dalam tikus meningkat dengan ketara. Oleh itu, bioperolehan oral 
andrographolide rendah terutamanya disebabkan oleh keterlarutan air yang rendah.  
xix 
 Bioperolehan andrographolide yang rendah mungkin juga disebabkan oleh metabolisme 
laluan pertama.  
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BIOAVAILABILITY STUDIES OF ANDROGRAPHOLIDE IN RATS 
ABSTRACT 
A simple, specific and sensitive high performance liquid chromatography 
(HPLC-UV) analytical method has been developed and validated for detection and 
quantification of andrographolide level in the plasma. The standard curve was linear 
from 31.3ng/mL to 2000ng/mL. The coefficient of variation (C.V.) values of this 
method was less than 12% for both within- and between-day validation. The accuracy 
for both within- and between-day validation ranged from 90.3% to 103.3% and 93.5% to 
103.9% respectively. The absolute recovery for andrographolide was more than 67.3%. 
Andrographolide in working solution was stable up to 6 months. Nevertheless, it was 
only stable in plasma up to 2 hours, probably due to high protein-binding. Pure 
andrographolide was poorly soluble in water. Its aqueous solubility increased when 
physically mixed with polymer polyvinylpyrrolidone (PVP) K25. In vitro studies 
showed that the solubility of andrographolide increased when increased amount of PVP 
K25 was added. Andrographolide-PVP K25 complex was stable in pH1.2, 4.5 and 7.0 
up to 8 hours, with more than 90% remaining undegraded. In vivo rat studies showed 
that pure andrographolide was barely detected in plasma although given at high dose of 
50mg/kg. However, by mixing it with water-soluble polymer PVP K25, the 
bioavailability of andrographolide in rats increased significantly. Therefore, poor 
bioavailability of andrographolide is mainly due to its poor aqueous solubility. The poor 
bioavailability of andrographolide may also be to a lesser extent, due to first pass 
metabolism.  
xxi 
1 
 
CHAPTER 1: INTRODUCTION 
1.1 Bioavailability and oral drug absorption 
Bioavailability is defined as the rate and extent at which the active moiety is 
absorbed from a drug and becomes available at the site of action (FDA, 2003). A 
drug which is administered by intravenous route is considered 100% bioavailable, as 
it is directly introduced into the systemic circulation.  Extravascular administration 
includes all routes of administration in which the drug is not delivered directly to the 
bloodstream. Any drug administered extravascularly must first be absorbed from its 
site of administration to subsequently enter the systemic circulation. The 
bioavailability of any drug given by extravascular route can range from zero to 100 
percent, depending on the fraction of dose that reaches the systemic circulation 
unchanged. Therefore, the therapeutic efficacy of a drug administered by 
extravascular route is directly related to its bioavailability. 
Absorption is the process of transferring chemical substances from the 
gastrointestinal tract through its wall into the bloodstream and lymphatic system (Liu, 
Wang & Hu, 2008). For absorption to occur, a drug must undergo dissolution in the 
gastrointestinal fluid, and must remain soluble and stable throughout the 
gastrointestinal tract. The most frequently used and preferred mode of drug 
administration is the oral route, as it is less invasive, convenient and widely accepted 
by patient. Following oral administration, a drug in the dosage form must dissolve 
before it crosses the gastrointestinal wall and subsequently enters the systemic 
circulation, and then transported to its site of action (Ashford, 2002a). Therefore, the 
in vivo dissolution and intestinal permeation are two critical elements in the oral 
absorption of a drug.  
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1.2 Transport of drug molecules across the gastrointestinal membrane 
The main cellular barrier to drug absorption is the gastrointestinal membrane that 
separates the lumen of the stomach and intestines from the systemic circulation. This 
barrier is semipermeable in nature which selectively prevents the passage of some 
molecules. In addition, a number of transporter proteins are found in the membrane. 
These transporter proteins also play a role in the transportation of materials back and 
forth across the membrane.  
There are two main mechanisms of drug transport across the gastrointestinal 
epithelium: transcellular and paracellular. The mechanisms of drug transport across 
the epithelial membrane are shown in Figure 1.1. 
 
 
 
 
 
 
 
1. Transcellular 
2. Paracellular 
3. Active uptake into the cell 
4. Active efflux out of cell 
Figure 1.1: Mechanisms of drug transport across an epithelial membrane 
3 4 
1 2 
Apical side 
  
    
  
Basolateral side 
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1.2.1 Paracellular pathway 
The paracellular (between the cell) pathway involves transport of molecules through 
the aqueous pores between the cells. Small hydrophilic molecules, such as water, 
urea, sugars, amino acids and calcium, can cross the gastrointestinal epithelium via 
paracellular pathway. The molecular weight cut-off for this pathway is considered to 
be 200 Daltons, although passage of some larger molecules is possible (Lennernas, 
2007). Drug transport by paracellular route is minimal due to the presence of tight 
junctions between the cells. 
1.2.2 Transcellular pathway 
Transcellular pathway involves the passage of drug across the cell. It is the most 
common route of drug transport across the gastrointestinal membrane. Transcellular 
pathway can be further divided into passive diffusion, carrier-mediated transport and 
vesicular transport. 
1.2.2(a) Passive diffusion 
Passive diffusion is the most important pathway for drug molecules to cross the gut 
wall. In this process, drug molecules pass through lipoidal membranes from a region 
of high concentration in the intestinal lumen to a region of lower concentration in the 
blood.  
The mechanism of the passive diffusion follows Fick‘s Law, whereby the absorption 
rate is proportional to the drug concentration and the surface area. The passage of 
drug across a membrane is affected by three major molecular properties: size, 
lipophilicity and degree of ionization. These properties, together with the nature of 
the membrane, determine the overall speed of movement of a drug across the 
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membrane. Generally, the higher the lipophilicity of a drug the greater its 
permeability. Molecular size has a major impact on movement through membranes. 
This is probably due to the rigidity of cell membrane lipid bilayer, which impedes 
drug movement. The larger the molecule, the slower its movement across membrane. 
Degree of ionization is the third major constraint to transmembrane passage. In 
general, charged molecules are not as permeable as the corresponding uncharged 
molecules. 
According to the Lipinski‘s Rule of Five, a compound is more likely to be membrane 
permeable and easily absorbed if the following criteria are met: its molecular weight 
is less than 500, the calculated octanol-water partition coefficient (log P) is less than 
5, the number of hydrogen donor is less than 5, and less than 10 hydrogen-bond 
acceptors (Lipinski et al, 2012).  
1.2.2(b) Carrier-mediated transport 
Carrier-mediated transport can be further divided into active transport and facilitated 
diffusion. 
Active transport mechanism requires the presence of carrier proteins to form carrier-
drug complex, and carry them through the membrane to the bloodstream. This allows 
drugs to be transported against the concentration gradient across a cell membrane. 
This process requires energy input and is also temperature-dependent (Zhou and Qiu, 
2009). There are many types of transporters families in the small intestine, which can 
be present either on the apical or on the basolateral cell membrane. These include 
amino acid transporters, organic anion transporters, peptide transporters, vitamin 
transporters and multidrug resistant proteins. Due to limited capacity, these carriers 
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can be saturated. In addition, carrier-mediated transport can be competitively 
inhibited by substrate analogs or specific inhibitors.  
Facilitated diffusion differs from active transport is that the drug moves along the 
concentration gradient, and hence does not consume energy. This process is saturable 
and is subjected to inhibition by competitive inhibitors (Zhou and Qiu, 2009). 
Facilitated diffusion plays a minor role in drug absorption, except in the case of 
nucleoside analogs.  
1.2.2(c) Vesicular transport 
Vesicular transport is a process in which cell absorbs molecules from outside the cell 
by engulfing it with their cell membrane. This process is subdivided into three 
categories: pinocytosis, phagocytosis and endocytosis. Vesicular transport plays a 
minor role in drug absorption. 
1.3 Factors affecting drug absorption 
For most drugs, the optimum site for drug absorption after oral administration is the 
upper portion of the small intestine, particularly the duodenum region. The presence 
of fold-like projections, known as villi and microvilli in the intestinal mucosa further 
increase the surface area for better absorption. A large network of capillaries and 
lymphatic vessels perfuse the duodenal region. Once the drug is absorbed from the 
small intestine, it enters to the hepatic-portal vein and the liver via the mesenteric 
vessels before reaching the bloodstream (Shargel, 2005).  
The systemic absorption of an oral drug depends on three aspects: the physiological 
factors of the gastrointestinal tract, the physiochemical properties of the drug, and 
the properties of the dosage form. 
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1.3.1 Physiological factors 
The pH of the gastrointestinal fluids changes along the gastrointestinal tract. For an 
ionisable drug, its dissolution, chemical stability and absorption may be affected by 
gastrointestinal pH. Chemical degradation due to pH-dependent hydrolysis can occur 
in gastrointestinal tract. As a result, incomplete bioavailability may occur, as only a 
fraction of the administered dose reaches the systemic circulation in the form of 
intact drug (Ashford, 2002b).  
Gastrointestinal motility and transit time also affect oral drug absorption. During the 
fasted or interdigestive state, the ―migrating motor complex‖ (MMC) acts as a 
propulsive movement that empties the upper GI tract to the caecum. The stomach 
first experiences a quiescent phase that lasts approximately one hour. This is 
followed by irregular contractions, and ends with high amplitude ―house keeper 
contractions‖ that empties the residual contents further down the alimentary canal. 
On the other hand, the stomach undergoes irregular contractions in the fed state, 
where mixing of intestinal contents and advancing of the intestinal stream toward the 
colon in short segments occur (Shargel, 2005). During this phase, solids larger than 
2mm are retained whereas smaller particles and liquids are emptied. The rate of 
stomach emptying is also influenced by food content. Carbohydrates are emptied 
more rapidly than proteins and fats. It is also notable that gastrointestinal motility 
may be affected by drug administered. For example, anticholinergic drugs may 
reduce the rate of gastric emptying and gastrointestinal motility, thus their transit 
time would be increased.  
The bioavailability of a drug may be reduced by pre-systemic metabolism by the 
enzymes in the gut wall and liver. The rapid metabolism of an orally administered 
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drug before reaching the general circulation is known as first-pass effect. The 
cytochrome P450s (CYPs) constitute a superfamily of heme-thiolate proteins that 
catalyse the biotransformation of xenobiotics, including drugs and toxins. In humans, 
approximately 50% of the overall elimination of commonly used drugs can be 
attributed to P450 enzymes. The major forms are CYP3A (about 30% of total P450) 
and CYP2C (about 20%) isoenzymes (Shimada et al, 1994). One example of drug 
with high pre-systemic metabolism is nitroglycerin. To overcome first-pass effect, 
nitroglycerin is given sublingually, topically or by nasal route due to very poor oral 
bioavailability (Shargel, 2005). 
The presence of food may affect the bioavailability of a drug. Generally, meals that 
are high in total calories and fat content are more likely to affect gastrointestinal 
physiology and hence the bioavailability of a drug. Some drugs are capable of 
forming insoluble complex with diet component, thereby reducing the drug 
absorption. For example, tetracycline forms non-absorbable complexes with calcium 
and ions. Therefore, patients are advised not to take milk, antacids or iron 
preparation at the same time of day as tetracycline (Shargel, 2005).  
Diseases that cause changes in gastrointestinal pH, blood flow, motility, gut wall 
permeability, alteration of GI flora, digestive enzyme secretion or bile secretion may 
affect oral drug absorption. For example in diarrhoea, inadequate absorption of a 
drug may happen due to decrease in transit time (Shargel, 2005).  
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1.3.2 Physiochemical properties of a drug 
To achieve a pharmacological activity, a drug molecule must exhibit certain 
solubility in physiological intestinal fluids to be present in the dissolved state at the 
site of absorption.  
When solid particles are in the gastrointestinal tract, a saturated layer of drug 
solution is formed at the surface area of the solid particle. This stagnant layer 
between the solid particle and bulk solution is known as diffusion layer. Thus, the 
concentration at the solid surface is assumed to be its solubility and a concentration 
gradient is formed traversing the stagnant layer. According to Noyes-Whitney 
equation: 
  
  
 
   
 
         ---------------  Equation 1.1 
  
  
 = Dissolution rate; K = Dissolution rate constant; D = Dissolution coefficient of a 
drug; S = Surface area of the undissolved drug; h = Thickness of the diffusion layer; 
Cs = Equilibrium solubility of the drug in the GI fluid; C = Drug concentration 
This equation shows that the dissolution of drug in the GI tract is governed by two 
variables: solubility and surface area of the drug. For the same dose strength, smaller 
particles lead to a larger surface area and faster dissolution rate. A reduction in 
particle size increases the effective surface area of a drug. This enhances water 
penetration into the drug particles, and increases the dissolution rate. Hence, particle 
size reduction will increase bioavailability if the drug absorption is dissolution-rate 
limited.  
A drug molecule needs to have sufficient lipophilicity to cross the lipid bilayer of the 
cell membrane. This is important for drugs that are absorbed via passive diffusion. 
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Nevertheless, this does not imply that the higher the lipophilicity, the better the 
absorption. Drug molecule with extremely high lipophilicity will bind too tightly to 
the cell membrane, making absorption impossible to occur. 
In general, uncharged molecules are more permeable compared to the corresponding 
charged species when the compound is absorbed via passive diffusion. For weak 
acids and bases, the pH at which the majority of the species remain uncharged should 
be considered, as the solubility of weak acids or bases in the gastrointestinal tract is 
greatly affected by the degree of ionization.  
Passive absorption is limited by the size of the molecule due to the well-packed 
structure of the membrane lipid bilayer. According to Lipinski‘s Rule of Five, the 
optimal molecular weight that facilitates absorption is less than 500 (Lipinski et al, 
2012). 
Polymorphism is the arrangement of drug in various crystal forms. Although sharing 
the same chemical structure, polymorphs have different physical properties, such as 
density, hardness and solubility. A metastable polymorph usually exhibits greater 
dissolution rate compared to the corresponding stable polymorph. The stability of 
each form is important, as a metastable form may convert to a more stable form over 
time (Shargel, 2005).  
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1.3.3 Formulation factor 
Drugs are generally given to patients as formulated drug products. The formulated 
drug products are made up of the active ingredient and the excipients. The type of 
dosage form, such as tablet, capsule, oral solution, suspension, suppository and the 
nature of the excipients in the drug product, will affect the dissolution rate and the 
bioavailability of the drug.  
Prior to dissolution, the drug product must disintegrate into small particles and 
release the drug. Therefore, drug in liquid dosage forms, such as oral solutions, 
emulsions and suspensions are more readily absorbed compared to solid dosage 
forms like tablets or capsules. 
Although they should be pharmacodynamically inert, excipients may amend the 
functionality of the drug and the bioavailability of the drug from the dosage form 
(Shargel, 2005). For instance, excessive quantity of magnesium stearate, a 
hydrophobic lubricant, may repel water and reduce dissolution. On the other hand, 
low concentrations of surfactants increase the dissolution rate of the drug by 
decreasing in surface tension. Nevertheless, the drug dissolution rate decreases with 
higher surfactant concentrations, due to formation of micelles with the drug.  
1.4 Andrographis paniculata 
Andrographis paniculata (Burm.f) Nees is a medicinal herb belonging to family 
Acanthaceae in plant kingdom. Due to its extremely bitter taste, it is commonly 
known as ―hempedu bumi‖, which literally means ―bile of the earth‖ in Malaysia. 
Andrographis paniculata is an annual herb growing to a height of 0.50-1.0m. The 
stems are dark green, quadranecular and branches profusely. The leaves are green, 
11 
 
lanceolate, simple, opposite, and glabrous with a short petiole. The leaf size is 
reduced as the plant matures. The flowers are borne on terminal, white in colour with 
reddish-purple spots on the petals. The flowers are bisexual in nature, about 1-2cm 
long, without distinct odour and very irregular in shape. The plant bears small seeds 
which are abundant, linear-oblong in shape and yellowish-brown in colour 
(Subramanian, 2012). 
Andrographis paniculata is commonly found in wastelands and grasslands in 
countries such as Southeast Asia, China, Taiwan, India and Sri Lanka. The aerial 
parts and roots have been used for centuries in Asia and Europe as folklore remedy 
for a wide spectrum of ailments or as herbal supplement. In India, the herb is a 
predominant constituent of at least 26 Ayurvedic formulations used to treat liver 
disorders or neoplasms. In traditional Chinese medicine, Andrographis paniculata is 
reported as a cold property herb and is used for latent-heat clearing and to expel 
toxins (Varma et al, 2011). In Scandinavian countries, the Kan Jang capsule, which 
consists of the extracts of Andrographis paniculata and Eleutherococcus senticosus, 
is commonly used to prevent and treat the common cold. In addition, Andrographis 
paniculata has also been included into ―WHO monographs on selected medicinal 
plants, volume 2‖ (WHO, 2003). The monographs served as a valuable scientific 
reference for the healthcare authority and scientist, as well as play an important role 
in promoting safe and proper use of medicinal plants globally.  
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Figure 1.2: Andrographis paniculata and flowers, scale approximately 0.8x 
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1.4.1 Andrographolide 
Andrographis paniculata contains diterpenoids, polyphenols and flavonoids. Up to 
date there are more than 20 diterpenoids and over ten flavonoids have been reported 
from Andrographis paniculata (Chao and Lin, 2010). Andrographolide is the 
primary bioactive constituent of the medicinal plant. The molecular formula and 
weight of andrographolide is C20H30O5 and 350.45g/mol respectively. It is the major 
diterpenoid in Andrographis paniculata. It makes up about 4%, 0.8-1.2%, and 0.5-
0.6% in dried whole plant, stem and leaf extracts respectively (Chao and Lin, 2010). 
Andrographolide is present in all parts of the plant but is abundant in the stems and 
leaves. It is a colourless, crystalline solid with extremely bitter taste. The systematic 
name is 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5, 8α-dimethyl-2-methylene-
1-naphthalenyl]ethylidine]dihydro-4-hydroxy-2(3H)-furanone (Smith III et al, 1982). 
 
 
 
Figure 1.3: Chemical structure of andrographolide (Source: Sigma Aldrich) 
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1.4.2 Medicinal benefits of andrographolide 
Androgapholide, the principal bioactive compound found in Andrographis 
paniculata, is reported to exhibit vast range of biological activities. 
In animal studies, andrographolide showed significant hepatoprotective effect against 
liver damage induced by paracetamol (Handa and Sharma, 1990; Visen et al, 1993), 
galactosamine (Handa and Sharma, 1990), carbon tetrachloride (Kapil et al, 1993), 
or tert-butylhydroperoxide (Kapil et al, 1993). On the other hand, Kapir and 
colleagues (1993) found that other diterpenoids, such as andrographiside and 
neoandrographolide, exhibited stronger hepatoprotective effect than andrographolide. 
Hence, the hepatoprotective effect of the plant may not solely be due to 
andrographolide, but it is the synergistic effect of other phytochemicals present in the 
plant. 
Investigations from all over the world showed that andrographolide possessed 
antineoplastic activities. In vitro studies showed that andrographolide or its extract 
exhibited anticancer activity by acting both directly and indirectly on the cancer cells. 
Proliferation of cancer cells was inhibited by induction of cell-cycle arrest, apoptosis 
or necrosis (Ji et al, 2007; Li et al, 2007; Manikam and Stanslas, 2009; Shi et al, 
2009). In addition, andrographolide may exhibit immunomodulatory activity by 
triggering body‘s own immune system against cancerous cells. Most of the 
experiments carried out were on in vitro cellular toxicity assays with different 
concentrations. More studies are needed on animal models of cancer or on human in 
order to draw a conclusion about the anticancer activity of andrographolide (Varma 
et al, 2011). 
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Studies revealed that andrographolide exerts its anti-inflammatory effects by 
reducing the expression of several pro-inflammatory mediators. Andrographolide 
had been shown to inhibit NF-kβ signalling pathway by binding to deoxyribonucleic 
acid, thus reducing the expression of pro-inflammatory proteins in neutrophils in 
many in vitro (cell culture) and in vivo studies (animals)(Hidalgo et al, 2005; Xia et 
al, 2014). NF-kβ is thought to be the regulating genes responsible for both the innate 
and adaptive immunity. It was reported that andrographolide suppressed the 
production of other pro-inflammatory proteins like nitric oxide synthetase (iNOS), 
and TNF-α (Chiou et al 1998; Chiou et al 2000; Qin et al, 2006). In addition, 
evidence also showed that the anti-inflammatory activities of andrographolide could 
be due to the interference with intracellular signaling pathway involved in the 
cytokine expression, such as IL-2, TNF-α, and IFN-2 (Chao and Lin, 2010). 
Subramanian and colleagues (2008) demonstrated that andrographolide caused a 
significant reduction in peak blood glucose and area under the curve in diabetic rats, 
and suggested that the antidiabetic activity may due to α-glucosidase and α-amylase 
inhibition. In rat studies conducted by Lin et al. (2009), andrographolide was 
reported to exhibit antioedema and analgesic activities in a concentration dependent 
manner. However, more in vivo studies are needed for studying the antidiabetic, 
antioedema and analgesic activities of andrographolide. 
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1.5  Pharmacokinetic studies of andrographolide 
To date, there is little information about the pharmacokinetic studies of 
andrographolide in animals and humans. Panossian and colleagues (2000) conducted 
pharmacokinetic studies in rats and humans using Andrographis paniculata extract 
and Kan Kang tablets. Wangboonskul and colleagues (2006) conducted 
pharmacokinetic study of Andrographis paniculata tablets in healthy male volunteers. 
Nevertheless, for human studies conducted by these researches, conclusion could not 
be drawn due to low number of volunteers involved. Ye and colleagues (2008) 
studied the oral bioavailability of andrographolide in rats and the reported absolute 
bioavailability of andrographolide was 2.67%. This finding was in contrast with 
Panossian et al. whereby the reported oral bioavailability of andrographolide was 91% 
at a dose of 20mg/kg, but reduced to 21.4% when the dose was increased to 
200mg/kg. 
Maiti et al. (2010) compared the oral bioavailability of pure andrographolide and its 
herbosome complex at a dose of 25mg/kg. The bioavailability of the herbosome 
complex was higher than the pure form and the complex maintained its effective 
plasma concentration for a longer period of time. 
Chellampillai and Pawar (2011) compared the bioavailability of andrographolide 
from optimised nanoparticles and pure andrographolide in male albino Wistar rats at 
a dose of 10mg/kg. There was an almost 2.2 fold increase in oral bioavailability of 
andrographolide from nanoparticle suspension compared to the pure form. The 
reported AUC0→∞ for pure andrographolide and andrographolide nanoparticles was 
2.169µg.h/mL and 4.807µg.h/mL, respectively. 
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1.6 Scope of study 
Several studies suggested that andrographolide possesses beneficial health effects 
including anticancer and anti-inflammatory activities. The actual beneficial effects to 
human cannot be fully realised as information regarding its bioavailability is limited. 
Therefore, the present study was focused on investigation of the bioavailability of 
andrographolide and to elucidate the possible factors affecting its bioavailability. 
The objectives of the present study are: 
1. To develop a High Performance Liquid Chromatography (HPLC) method to detect 
and quantify the amount of andrographolide in human and rat plasma. 
2. To study the potential of polyvinylpyrrolidone (PVP) K25 in enhancing the 
aqueous solubility of andrographolide.  
3. To investigate the bioavailability and pharmacokinetics of pure andrographolide 
and mixture of pure andrographolide with polyvinylpyrrolidone K25 in rats. The 
term ‗pure‘ was used throughout this study in order to differentiate andrographolide 
with 98% purity from andrographolide extract. 
4. To investigate the potential influence of cytochrome P450 and P-glycoprotein in 
limiting the bioavailability of andrographolide. 
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CHAPTER 2:  DEVELOPMENT OF SIMPLE HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC) METHOD WITH ULTRAVIOLET 
(UV) DETECTION FOR ANALYSIS OF ANDROGRAPHOLIDE 
IN HUMAN AND RAT PLASMA 
2.1 Introduction 
Andrographis paniculata is a traditional plant which is used in Asia for common 
cold, diarrhea, and fever associated with infectious diseases. The main active 
component of Andrographis paniculata is andrographolide, a colourless, bitter and 
crystalline diterpene lactone.  
Several methods have been developed for the determination of andrographolide in 
plasma. Determination of andrographolide in rat whole blood, rabbit plasma and 
chicken plasma by HPLC-UV method has been reported, with a limit of 
quantification of 0.053µg/mL, 0.05µg/mL, and 0.04µg/mL respectively (Suo, Zhang 
and Wang, 2007; Chen et al, 2007; Liu et al, 2009). There are shortcomings of these 
methods: analysis of compound in rat whole blood is not advisable as the 
components in blood will cause interference in many assay techniques and this will 
damage the chromatography column easily. Both rabbit and chicken are not suitable 
models for pharmacokinetic study as their digestive systems are less complicated 
compared to humans.  
There are also reports of determination of andrographolide in human plasma by 
liquid-chromatography-electroscopy ionisation tandem mass spectrometry (HPLC-
ES/MS), with the limit of quantification of 9.9ng/mL and 1ng/mL respectively (Gu 
et al, 2007, Xu et al, 2009). However, the method required use of expensive 
equipment and the sample preparation is very much laborious and complicated. 
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Although various analytical methods have been developed to quantify 
andrographolide in biological samples, HPLC-UV remains the preferred method as it 
is simple, rapid, specific, sensitive and economical. Therefore, developing a HPLC-
UV method that fulfils the criteria mentioned, as well as with high efficiency and 
reproducibility form the basis of this part of study.  The method should be able to 
detect and quantify andrographolide in both human and rat plasma, and subsequently 
can be used in the pharmacokinetic studies of andrographolide in rats.  
2.2 Materials and reagents 
Andrographolide powder of 98% purity was obtained from Sunrise Nutrachem 
Group (Qingdao, China). The standard of andrographolide (98% purity) was 
purchased from Sigma Aldrich (St.Louis, MO, USA). Carbamazepine was obtained 
from Hovid Sdn. Bhd (Ipoh, Perak, Malaysia). Both the andrographolide and 
carbamazepine were packed in sealed glass bottle, stored at fridge before use. 
Analytical grade acetonitrile (ACN) and acetic acid were purchased from Merck 
(Darmstadt, Germany). Human blank plasma was obtained from Penang General 
Hospital (Pulau Pinang, Malaysia).  
2.3  Instrumentation and chromatographic conditions 
UV-viscible spectrophotometric analysis was carried out on a Genesys 10S UV-Vis 
spectrophotometer (Waltham, MA, USA). The maximum absorbance of 
andrographolide was recorded at 229nm. 
The chromatographic system composed of a Jasco PU-980 pump (Jasco, Hachioji 
City, Tokyo, Japan), a Gilson UV/Vis 151 detector (Middleton, WI, USA) and a 
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Hitachi D-2500 chromato-integrator (Hitachi, Tokyo, Japan). The detection 
wavelength was set at 229nm and the sensitivity was set at 0.002 AUFS.  
The mobile phase consisted of ACN and distilled water, at a ratio of 30:70, with 0.05% 
of acetic acid added to the distilled water to provide an acidic environment. The 
mobile phase was vacuum filtered with 0.45µm HNWP04700 nylon membrane filter 
paper (Millipore, USA) prior to use. Chromatographic separation was achieved on a 
Zorbax Eclipse XDB-C18 column (4.6mm x 250mm, 5µm, Agilent, USA), fitted 
with a refillable guard column (Upchurch Scientific, Oak Harbour, WA, USA), 
packed with Perisorb RP-18 (30-40µm, pelliular, Upchurch Scientific, Oak Harbour, 
WA, USA). 
The isocratic flow rate was set at 1.0mL/min and the injection volume was 50µL. 
The column temperature was maintained at room temperature of 25°C throughout 
the analysis.  
2.4  Preparation of stock and working solution 
Fifty milligram of andrographolide standard was accurately weighed in a 50mL 
volumetric flask. The volume was then adjusted to 50mL with methanol to make up 
a stock solution of 1mg/mL. To prepare a secondary stock solution of 200µg/mL, an 
aliquot of 5.0mL of the primary stock solution was transferred into a 25mL 
volumetric flask and the volume was made up to 25mL. 
The internal standard carbamazepine was accurately weighed (25mg) in a 50mL 
volumetric flask. The volume was adjusted to 50mL with methanol to make up a 
stock solution of 0.5mg/mL. Further dilutions with methanol were performed to 
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obtain a working solution of 2.5µg/mL. All solutions were kept in amber glass bottle 
sealed with parafilm and stored at 4°C until assay.  
2.5 Standard solutions and calibration curves 
In order to construct calibration curves of andrographolide in plasma, 10mL of 
pooled human blank plasma was spiked with 100µL aliquot of the 200µg/mL stock 
solution to obtain a concentration of 2000ng/mL. Serial dilutions were performed 
with pooled human plasma to obtain a series of concentrations of 1000.0, 500.0, 
250.0, 125.0, 62.5, 31.3 ng/mL. 
A hundred microliter of plasma sample, 50µL of carbamazepine 2.5µg/mL and 5mL 
of chloroform were pipetted into a centrifuge tube with a screw cap. The mixture was 
vortex-mixed for 60 seconds, and then centrifuged at 12800g for 15 minutes. 
The organic layer was transferred to a reactival and evaporated to dryness at 40°C 
under the gentle stream of nitrogen. The residue samples were stored at -20°C until 
analysis. Prior to analysis, the samples were brought to room temperature, 
reconstituted with 100µL of mobile phase and vortexed for 60 seconds. 50µL of the 
resulting supernatant was then injected into the HPLC system.  
2.6 Assay validation 
Blank human plasma was analysed to demonstrate the absence of interfering 
endogenous peaks. Interference from andrographolide was also investigated by 
analysing the spiked concentration (0.5µg/mL) in blank human plasma. 
Standard calibration curves were constructed by spiking pooled human plasma with a 
known amount of andrographolide at a concentration range of 31.3—2000ng/mL. 
These plasma standards were also used to determine the within-day and between-day 
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precision and accuracy six times on the same day and continuously for six days 
(n=6). Quantification of samples was performed by using peak height ratio of the 
andrographolide over the internal standard (carbamazepine). The mean recoveries of 
andrographolide from plasma were calculated by comparing the response of 
andrographolide and internal standard obtained after extraction, with mean peak 
areas of the same amounts of unextracted solutions. 
The limit of detection (LOD) was defined as the lowest concentration with detectable 
response. The limit of quantification was defined as the lowest quantifiable 
concentration with satisfactory between-day and within-day precision and accuracy 
of less than 20% for both coefficient of variation and percentage of error. 
2.7 Stability 
Andrographolide stock solution of 2000ng/mL was assessed for short-term and long 
term stability. The stock solutions were kept in 4°C refrigerator. The concentrations 
of the stability samples were determined by comparing the concentrations of stability 
test samples to those of corresponding freshly prepared samples. A replicate of n=3 
was conducted for each sample. Data were presented in mean percentage.  
To assess the stability of andrographolide in spiked human plasma, three aliquots of 
low (31.3ng/mL), medium (250ng/mL) and high (2000ng/mL) concentrations of 
andrographolide plasma samples were used. The samples were stored in a freezer (-
20°C). The concentrations of the stability samples were determined by comparing 
the concentrations of stability test samples to those of corresponding freshly prepared 
samples. A replicate of n=3 was conducted for each sample and data was presented 
in mean percentage.   
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2.8  Results 
Figures 2.1(a) and 2.1(b) show the chromatograms of the blank human plasma and 
human plasma spiked with 0.5µg/mL of andrographolide. It can be seen that 
andrographolide is well separated under these chromatographic conditions and free 
of interference from endogenous compounds in human plasma. The mean retention 
times for andrographolide and carbamazepine were 7.9±0.1 and 13.8±0.1 
respectively. The total run time for each injection was approximately 15 minutes. 
The extraction recovery, within-day and between-day accuracy and precision values 
for andrographolide are shown in Table 2.1. The accuracy of the assay method at all 
the concentrations evaluated was between 90.3% and 105.9%.  The precision, which 
is expressed as the coefficient of variation (C.V) were between 3.1% and 12.0%. The 
mean extraction recovery for andrographolide at the concentrations studied were 
between 67.3% and 87.6%, whereas carbamazepine was between 88.0% and 105.3%.  
The limit of detection (LOD) of the present method was 15.7ng/mL, whereas the 
limit of quantification (LOQ) was 31.3ng/mL. The standard calibration curve (n=7) 
was found to be linear over the concentration range of 31.3 – 2000ng/mL. The 
equation of calibration curve was y=0.0005x.  
Andrographolide stock solution was stable up to 6 months at 4°C. Nevertheless, 
when it was spiked in human plasma, andrographolide was stable up to 2 hours at 
minus 20°C. Concentration of andrographolide in plasma was found to drop 15% of 
its original concentrations at 24 hours although this was not observed in its stock 
solutions.  
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                     2.1A                                                                     2.1 B 
Figure 2.1A: Blank human plasma 
Figure 2.1B: Human plasma spiked with (1) 1µg/mL andrographolide and (2) 
2.5µg/mL carbamazepine. 
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